PF-219,061

PF-219,061
Clinical data
Routes of; administration	Nasal
Legal status
Legal status	Investigational (discontinued);
Identifiers
	IUPAC name (R)-3-(4-propylmorpholin-2-yl)phenol;
CAS Number	710654-74-3 ;
PubChem CID	9794475;
ChemSpider	7970242 ;
CompTox Dashboard (EPA)	DTXSID90430791 ;
Chemical and physical data
Formula	C13H19NO2
Molar mass	221.300 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCN1CCO[C@@H](C1)C2=CC(=CC=C2)O;
	InChI InChI=1S/C13H19NO2/c1-2-6-14-7-8-16-13(10-14)11-4-3-5-12(15)9-11/h3-5,9,13,15H,2,6-8,10H2,1H3/t13-/m0/s1 ; Key:WYEGTIGJSHGEID-ZDUSSCGKSA-N ;
	(what is this?) (verify)

PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D₃ receptor.[1][2] It was under development as a potential medication for the treatment of female sexual dysfunction.[3][4] It did not advance into clinical trials.[5]

References

Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, et al. (December 2007). "Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route". Bioorganic & Medicinal Chemistry Letters. 17 (24): 6691–6. doi:10.1016/j.bmcl.2007.10.059. PMID 17976986.
Brioni, Jorge D.; Moreland, Robert B. (2006). "Dopamine D4 receptors and the regulation of penile erection". Drug Discovery Today: Therapeutic Strategies. 3 (4): 599. doi:10.1016/j.ddstr.2006.10.006.
Van Der Graaf et al. Selective Dopamine D3 Receptor Agonists for the Treatment of Sexual Dysfunction, WIPO Patent WO/2003/051370, granted to Pfizer
Attkins NJ, Heatherington AC, Phipps J, Verrier H, Huyghe I (July 2009). "Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 39 (7): 523–33. doi:10.1080/00498250902893775. PMID 19480558.
Cortés A, Moreno E, Rodríguez-Ruiz M, Canela EI, Casadó V (July 2016). "Targeting the dopamine D3 receptor: an overview of drug design strategies". Expert Opinion on Drug Discovery. 11 (7): 641–64. doi:10.1080/17460441.2016.1185413. PMID 27135354.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, et al. (December 2007). "Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route". Bioorganic & Medicinal Chemistry Letters. 17 (24): 6691–6. doi:10.1016/j.bmcl.2007.10.059. PMID 17976986.

[2] Brioni, Jorge D.; Moreland, Robert B. (2006). "Dopamine D4 receptors and the regulation of penile erection". Drug Discovery Today: Therapeutic Strategies. 3 (4): 599. doi:10.1016/j.ddstr.2006.10.006.

[3] Van Der Graaf et al. Selective Dopamine D3 Receptor Agonists for the Treatment of Sexual Dysfunction, WIPO Patent WO/2003/051370, granted to Pfizer

[4] Attkins NJ, Heatherington AC, Phipps J, Verrier H, Huyghe I (July 2009). "Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 39 (7): 523–33. doi:10.1080/00498250902893775. PMID 19480558.

[5] Cortés A, Moreno E, Rodríguez-Ruiz M, Canela EI, Casadó V (July 2016). "Targeting the dopamine D3 receptor: an overview of drug design strategies". Expert Opinion on Drug Discovery. 11 (7): 641–64. doi:10.1080/17460441.2016.1185413. PMID 27135354.

PF-219,061

See also

References